Australian biotechnology company Cartherics, which is developing immune cell therapies for cancer and other diseases, has been awarded a US$300,000 G-Rex grant to support clinical manufacturing of its lead product CTH-401 for upcoming clinical trials. …
Cartherics secures G-Rex grant to support its ‘in house’ manufacturing program
December 18, 2024 Australian Biotech
Latest Video
New Stories
-
Race Oncology appoints Opthea founder to its board
December 18, 2024 - - Australian Biotech -
New listings and higher prescription volumes driving PBS spend
December 18, 2024 - - Latest News -
If you have ovarian cancer, genomic testing may open up new treatment option
December 18, 2024 - - BioPharma -
Cartherics secures G-Rex grant to support its ‘in house’ manufacturing program
December 18, 2024 - - Australian Biotech -
Researchers say Australia’s first mRNA vaccine candidate could address COVID ‘immune imprinting’
December 18, 2024 - - Australian Biotech -
Government making it easier for itself on Safety Net but patients missing out
December 18, 2024 - - Latest News -
HTA implementation group waiting for ministerial direction on priorities
December 18, 2024 - - Latest News